What is the official website of Chiesi USA, Inc. ?

The official website of Chiesi USA, Inc. is http://chiesiusa.com/.

What is Chiesi USA, Inc.'s cybersecurity risk score?

Chiesi USA, Inc. has an AI-generated cybersecurity risk score of 686 out of 1000, indicating a Weak security posture according to Rankiteo's assessment.

How many security incidents has Chiesi USA, Inc. experienced?

According to Rankiteo, Chiesi USA, Inc. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Chiesi USA, Inc. been affected by any supply chain cyber incidents ?

According to Rankiteo, Chiesi USA, Inc. has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Chiesi USA, Inc. have SOC 2 Type 1 certification ?

According to Rankiteo, Chiesi USA, Inc. is not certified under SOC 2 Type 1.

Does Chiesi USA, Inc. have SOC 2 Type 2 certification ?

According to Rankiteo, Chiesi USA, Inc. does not hold a SOC 2 Type 2 certification.

Does Chiesi USA, Inc. comply with GDPR ?

According to Rankiteo, Chiesi USA, Inc. is not listed as GDPR compliant.

Does Chiesi USA, Inc. have PCI DSS certification ?

According to Rankiteo, Chiesi USA, Inc. does not currently maintain PCI DSS compliance.

Does Chiesi USA, Inc. comply with HIPAA ?

According to Rankiteo, Chiesi USA, Inc. is not compliant with HIPAA regulations.

Does Chiesi USA, Inc. have ISO 27001 certification ?

According to Rankiteo,Chiesi USA, Inc. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Chiesi USA, Inc. operate in ?

Chiesi USA, Inc. operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Chiesi USA, Inc. have ?

Chiesi USA, Inc. employs approximately 532 people worldwide.

Does Chiesi USA, Inc. own any subsidiaries ?

Chiesi USA, Inc. presently has no subsidiaries across any sectors.

How many LinkedIn followers does Chiesi USA, Inc. have ?

Chiesi USA, Inc.'s official LinkedIn profile has approximately 29,734 followers.

What is the NAICS classification code for Chiesi USA, Inc. ?

Chiesi USA, Inc. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Chiesi USA, Inc. have a Crunchbase profile ?

No, Chiesi USA, Inc. does not have a profile on Crunchbase.

Does Chiesi USA, Inc. have a LinkedIn profile ?

Yes, Chiesi USA, Inc. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/chiesi-usa.

How many cybersecurity incidents has Chiesi USA, Inc. experienced ?

As of June 21, 2026, Rankiteo reports that Chiesi USA, Inc. has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Chiesi USA, Inc. have ?

Chiesi USA, Inc. has an estimated 5,695 peer or competitor companies worldwide.

What types of cybersecurity incidents has Chiesi USA, Inc. faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

CUI

Boost Score +25 with badge (5 left)

686

/1000

Weak

711

/1000

Moderate

Chiesi USA, Inc. Vendor Cyber Rating & Cyber Score

chiesiusa.com

Add Your Compliance Badge

Chiesi USA, Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercialization of products for the hospital, rare disease and target office-based specialties. Our employees take an entrepreneurial approach to meet the evolving needs of our customers. As a Public Benefit Corporation, Chiesi USA is committed to operating as a good corporate citizen; positively impacting communities in which we live and serve. Headquartered in Cary NC, we employ over 360 employees in the United States. Previously known as Cornerstone Therapeutics, the company was acquired by the Chiesi Group in 2014. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. Headquartered in Parma, Italy, Chiesi

CUI A.I CyberSecurity Scoring

Scoring History

CUI

Chiesi USA, Inc. CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Chiesi USA, Inc.

Breach

12/2025

CHI1766442033

Loading…

A.I.

CUI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for CUI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Chiesi USA, Inc. in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Chiesi USA, Inc. in 2026.

Incident Types CUI vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Chiesi USA, Inc. in 2026.

Incident History - CUI (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Chiesi USA, Inc. Subsidiaries

CUI

Pharmaceutical Manufacturing

Website: http://chiesiusa.com/

Company Size: 201-500 employees

Chiesi GroupPharmaceutical Manufacturing

Chiesi Air USAPharmaceutical Manufacturing

Loading…

Chiesi USA, Inc. Similar Companies

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Loading…

NEWS

Chiesi USA, Inc. CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 26, 2025 08:00 AM

Chiesi USA Data Breach Investigation

Strauss Borrelli PLLC, a leading data breach law firm, is investigating Chiesi USA, Inc. (“Chiesi”) regarding its recent data breach.

Read Article

December 22, 2025 08:00 AM

Chiesi USA Data Breach Exposes SSNs & Medical Info

Chiesi USA, Inc., a specialty pharmaceutical company headquartered in Cary, North Carolina, recently reported a significant data breach...

Read Article

October 15, 2025 07:00 AM

Chiesi Announces FDA Acceptance of New Drug Application for its Triple Combination Inhaler for the Maintenance Treatment of Asthma

Asthma remains a significant health burden in the U.S., with more than 60% of adults continuing to experience frequent symptoms despite the...

Read Article

August 28, 2025 07:00 AM

Chiesi Loses Suit Over Drug Strength in Medicaid Rebate Program

Drugmaker Chiesi USA, Inc. failed to convince a federal judge that the Medicaid agency acted unlawfully when it determined what “new...

Read Article

March 29, 2021 07:00 AM

Chiesi USA Appoints Martin Marciniak as VP

CARY, N.C., March 29, 2021 (GLOBE NEWSWIRE) — Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56355

SUMMARY

GNU Savannah Administration Savane through 3.17 uses untrusted data as part of authorization.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-56347

SUMMARY

AVideo TopMenu plugin through version 26.0 contains a stored cross-site scripting vulnerability in menu item rendering due to missing output encoding of icon classes, URLs, and text labels. Attackers can inject malicious JavaScript through unescaped menu item fields that execute for all site visitors, potentially stealing session cookies or performing unauthorized actions.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.7

Exploitability

2.8

REFERENCES

CVE-2026-56346

SUMMARY

AVideo through version 25.0 contains an authentication bypass vulnerability in the decryptMessage.json.php endpoint that allows unauthenticated users to decrypt PGP messages. Remote attackers can submit private keys, ciphertext, and passphrases to perform server-side decryption without credentials, exposing key material to logs and enabling resource exhaustion attacks.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:L

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

3.9

REFERENCES

CVE-2026-56345

SUMMARY

AVideo through 29.0 contains an authorization bypass vulnerability in the Meet plugin's uploadRecordedVideo.json.php endpoint that derives the target users_id from the uploaded filename without verification. An attacker with knowledge of the Meet shared secret can craft a malicious file upload with a filename containing an arbitrary users_id to invoke passwordless User->login() and establish an authenticated session as any user including admin. Attackers can obtain the Meet shared secret through path-traversal vulnerabilities or timing attacks against checkToken.json.php, then POST a crafted file to uploadRecordedVideo.json.php with a filename like '1-anything.mp4' to hijack admin sessions and gain full account takeover.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.2

REFERENCES

CVE-2026-56342

SUMMARY

AVideo through version 27.0 contains a server-side request forgery vulnerability in plugin/Live/test.php that allows authenticated administrators to read arbitrary URLs via the statsURL parameter, which lacks isSSRFSafeURL() validation and accepts requests to private IP ranges and cloud metadata endpoints. Attackers can exploit this by crafting requests to internal services, cloud metadata endpoints like 169.254.169.254, and localhost to retrieve sensitive information including IAM credentials, internal service responses, and network configuration details.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 6.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…